idalopirdine

Small moleculeexperimental

Idalopirdine (INN; development code Lu AE58054) is a potent and selective 5-HT6 receptor antagonist under development by Lundbeck as an augmentation therapy for the treatment of cognitive deficits associated with Alzheimer's disease and schizophrenia. As of October 2013 it is in phase III clinical trials. — Wikipedia

Clinical trial activity

16 trials · 2 clinical orgs · 0 marketing orgs

Phase 1

Phase 2

Phase 3

Phase 4

Earliest trial started Nov 1, 2008 (NCT00810667)

Timeline

2000s

Jan 1, 2008
Earliest Phase 2 Sponsor(trial)

2010s

Jan 1, 2013
Earliest Phase 1 Sponsor(trial)
Jan 1, 2013
Earliest Phase 3 Sponsor(trial)

Indications

Studied for

Mechanism of action

Serotonin 6 (5-HT6) receptorANTAGONIST
HTR6 antagonist
- 5-hydroxytryptamine receptor 6 (HTR6) ↗

Chemistry & pharmacology

Loading structure…

SMILES

Fc1ccc2c(CCNCc3cccc(OCC(F)(F)C(F)F)c3)c[nH]c2c1

Mol. weight: 398.38 g/mol
Lipinski Ro5: Pass
Rule of 3: No
Chirality: Achiral Molecule
Inorganic: No
Polymer: No

Oral

Parenteral

Topical

Sources

WikipediaIdalopirdine ↗
ChEMBLCHEMBL3286580 ↗

Also known as

(2-(6-fluoro-1h-indol-3-yl)-ethyl)-(3-(2,2,3,3-tetrafluoropropoxy)benzyl)amine
[benzyl-7-14c]-idalopirdine
[ethyl-1-14c]-idalopirdine
idalopirdine
idalopirdine
idalopirdine
idalopirdine
idalopirdine
luae58054
lu ae58054
lu ae58054
lu ae58054
lu-ae58054
lu-ae58054
lu-ae58054

Clinical trials

NCT ID	Phase	Start date	Sponsor(s)
NCT03307993	Phase 1	Sep 22, 2017	Lundbeck
NCT02894515	Phase 1	Sep 1, 2016	Lundbeck
NCT02436486	Phase 1	May 1, 2015	Lundbeck
NCT02415907	Phase 1	Apr 1, 2015	Lundbeck
NCT02371707	Phase 1	Mar 1, 2015	Lundbeck
NCT02340195	Phase 1	Jan 1, 2015	Lundbeck
NCT02231450	Phase 1	Jul 1, 2014	Lundbeck
NCT02079246	Phase 3	Apr 1, 2014	Lundbeck
NCT02122692	Phase 1	Mar 1, 2014	Lundbeck
NCT02006654	Phase 3	Mar 1, 2014	Lundbeck, Otsuka
NCT02006641	Phase 3	Feb 1, 2014	Lundbeck, Otsuka
NCT02019394	Phase 1	Dec 1, 2013	Lundbeck
NCT01955161	Phase 3	Oct 1, 2013	Lundbeck, Otsuka
NCT01975779	Phase 1	Jul 1, 2013	Lundbeck
NCT01019421	Phase 2	Dec 1, 2009	Lundbeck
NCT00810667	Phase 2	Nov 1, 2008	Lundbeck

Showing 16 of 16 trials

Page 1 / 1

Organizations

Research & Development (2)

Organization	Org type	Trials	As lead sponsor	Phases	Earliest year
Lundbeck	For profit	16	16	3	2008
Otsuka	For profit	3	0	1	2013

2 organizations

Page 1 / 1